Literature DB >> 18956251

Nutritional management of PKU with glycomacropeptide from cheese whey.

D M Ney1, S T Gleason, S C van Calcar, E L MacLeod, K L Nelson, M R Etzel, G M Rice, J A Wolff.   

Abstract

Individuals with phenylketonuria (PKU) must follow a lifelong low-phenylalanine (Phe) diet to prevent neurological impairment. Compliance with the low-Phe diet is often poor owing to restriction in natural foods and the requirement for consumption of a Phe-free amino acid formula or medical food. Glycomacropeptide (GMP), a natural protein produced during cheese-making, is uniquely suited to a low-Phe diet because when isolated from cheese whey it contains minimal Phe (2.5-5 mg Phe/g protein). This paper reviews progress in evaluating the safety, acceptability and efficacy of GMP in the nutritional management of PKU. A variety of foods and beverages can be made with GMP to improve the taste, variety and convenience of the PKU diet. Sensory studies in individuals with PKU demonstrate that GMP foods are acceptable alternatives to amino acid medical foods. Studies in the PKU mouse model demonstrate that GMP supplemented with limiting indispensable amino acids provides a nutritionally adequate source of protein and improves the metabolic phenotype by reducing concentrations of Phe in plasma and brain. A case report in an adult with classical PKU who followed the GMP diet for 10 weeks at home indicates safety, acceptability of GMP food products, a 13-14% reduction in blood Phe levels (p<0.05) and improved distribution of dietary protein throughout the day compared with the amino acid diet. In summary, food products made with GMP that is supplemented with limiting indispensable amino acids provide a palatable alternative source of protein that may improve dietary compliance and metabolic control of PKU.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956251      PMCID: PMC3633220          DOI: 10.1007/s10545-008-0952-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

Review 1.  Biological activities of bovine glycomacropeptide.

Authors:  E P Brody
Journal:  Br J Nutr       Date:  2000-11       Impact factor: 3.718

2.  The influence of phenylalanine intake on the chemistry and behaviour of a phenyl-ketonuric child.

Authors:  H BICKEL; J GERRARD; E M HICKMANS
Journal:  Acta Paediatr       Date:  1954-01       Impact factor: 2.299

3.  Phenylketonuria in adulthood: a collaborative study.

Authors:  R Koch; B Burton; G Hoganson; R Peterson; W Rhead; B Rouse; R Scott; J Wolff; A M Stern; F Guttler; M Nelson; F de la Cruz; J Coldwell; R Erbe; M T Geraghty; C Shear; J Thomas; C Azen
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

4.  Threonine kinetics at graded threonine intakes in young men.

Authors:  X H Zhao; Z M Wen; C N Meredith; D E Matthews; D M Bier; V R Young
Journal:  Am J Clin Nutr       Date:  1986-05       Impact factor: 7.045

Review 5.  Effects of ingestion of disproportionate amounts of amino acids.

Authors:  A E Harper; N J Benevenga; R M Wohlhueter
Journal:  Physiol Rev       Date:  1970-07       Impact factor: 37.312

6.  Effects of bovine alpha-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants.

Authors:  Wolfram M Brück; Michele Redgrave; Kieran M Tuohy; Bo Lönnerdal; Gitte Graverholt; Olle Hernell; Glenn R Gibson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-11       Impact factor: 2.839

7.  Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria.

Authors:  Denise M Ney; Angela K Hull; Sandra C van Calcar; Xiaowen Liu; Mark R Etzel
Journal:  J Nutr       Date:  2008-02       Impact factor: 4.798

8.  Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults.

Authors:  Rex A Moats; Kathryn D Moseley; Richard Koch; Marvin Nelson
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

9.  Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU.

Authors:  Kyungwha Lim; Sandra C van Calcar; Kathryn L Nelson; Sally T Gleason; Denise M Ney
Journal:  Mol Genet Metab       Date:  2007-07-23       Impact factor: 4.797

10.  Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Authors:  R Matalon; K Michals-Matalon; G Bhatia; A B Burlina; A P Burlina; C Braga; L Fiori; M Giovannini; E Grechanina; P Novikov; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2007-02-27       Impact factor: 4.750

View more
  27 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source.

Authors:  A Pinto; M F Almeida; P C Ramos; S Rocha; A Guimas; R Ribeiro; E Martins; A Bandeira; A MacDonald; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

3.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

4.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

Review 5.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

6.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

7.  Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.

Authors:  Patrick Solverson; Sangita G Murali; Adam S Brinkman; David W Nelson; Murray K Clayton; Chi-Liang Eric Yen; Denise M Ney
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-31       Impact factor: 4.310

Review 8.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

Review 9.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

10.  Purification and use of glycomacropeptide for nutritional management of phenylketonuria.

Authors:  Caitlin E Laclair; Denise M Ney; Erin L MacLeod; Mark R Etzel
Journal:  J Food Sci       Date:  2009 May-Jul       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.